Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancers|June 12, 2019
Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell TumorsRatnakar Singh, Zeeshan Fazal, Andrea K Corbet, et al.
Rwanda Journal of Medicine and Health Sciences|July 11, 2025
Knowledge and Utilization of Contraceptive Methods among Secondary School Female Adolescents in Rwamagana District, RwandaInnocent Ngerageze, Madeleine Mukeshimana, Aimable Nkurunziza, et al.
Molecular Oncology|September 5, 2021
Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapyRatnakar Singh, Zeeshan Fazal, Emmanuel Bikorimana, et al.
Translational Oncology|April 22, 2023
G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cellsAndrea K Corbet, Emmanuel Bikorimana, Raya I Boyd, et al.
Cancer Letters|September 7, 2024
Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancerMaría Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, et al.
Cancer Letters|March 24, 2025
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterationsYasuaki Uemoto, Chang-Ching A Lin, Bingnan Wang, et al.
Epigenetics|October 31, 2020
Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumoursZeeshan Fazal, Ratnakar Singh, Fang Fang, et al.
Cancer Medicine|November 2, 2020
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancerCostantine Albany, Zeeshan Fazal, Ratnakar Singh, et al.
Cancer Research Communications|July 28, 2023
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Pageof 3